We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

170 hedge funds and large institutions have $929M invested in CRISPR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

47% more capital invested

Capital invested by funds: $631M → $929M (+$298M)

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

10% more funds holding

Funds holding: 155 → 170 (+15)

7.11% more ownership

Funds ownership: 42.63% → 49.75% (+7.1%)

35% less call options, than puts

Call options by funds: $14.1M | Put options by funds: $21.6M

Holders
170
Holders Change
+15
Holders Change %
+9.68%
% of All Funds
3.68%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.13%
New
39
Increased
44
Reduced
38
Closed
23
Calls
$14.1M
Puts
$21.6M
Net Calls
-$7.58M
Net Calls Change
-$1.47M

Top Buyers

1
EC
EcoR1 Capital
California
+$57.7M
2
BB
BB Biotech
Switzerland
+$28M
3
CAM
Cormorant Asset Management
Massachusetts
+$27.7M
4
AIM
ARK Investment Management
Florida
+$24.1M
5
VVM
Versant Venture Management
California
+$22.1M

Top Sellers

1
FCM
Farallon Capital Management
California
-$18.2M
2
Two Sigma Investments
Two Sigma Investments
New York
-$15M
3
NLVP
New Leaf Venture Partners
New York
-$12.7M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$8.08M
5
AC
Armistice Capital
New York
-$3.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
VVM
1
Versant Venture Management
California
$152M +$22.1M +640,014 +18%
NMC
2
NEA Management Company
Maryland
$74.7M – – –
AIM
3
ARK Investment Management
Florida
$72.3M +$24.1M +697,907 +53%
EC
4
EcoR1 Capital
California
$67.1M +$57.7M +1,669,427 +799%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$52M +$21.2M +613,192 +73%
A
6
Abingworth
United Kingdom
$41.8M – – –
WRF
7
Waddell & Reed Financial
Kansas
$35.8M +$66.3K +1,918 +0.2%
CAM
8
Cormorant Asset Management
Massachusetts
$32.1M +$27.7M +800,000 +800%
CS
9
Credit Suisse
Switzerland
$31.8M +$4M +115,691 +15%
BB
10
BB Biotech
Switzerland
$28.9M +$28M +810,462 New
Federated Hermes
11
Federated Hermes
Pennsylvania
$27.3M – – –
FCM
12
Farallon Capital Management
California
$25.9M -$18.2M -525,000 -42%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$22.1M +$63.8K +1,845 +0.3%
BlackRock
14
BlackRock
New York
$21.4M -$1.34M -38,754 -6%
OTPPB
15
Ontario Teachers' Pension Plan Board
Ontario, Canada
$20.8M – – –
CCP
16
Clough Capital Partners
Massachusetts
$20.7M +$2.22M +64,200 +12%
Wells Fargo
17
Wells Fargo
California
$17.4M +$442K +12,786 +3%
GTP
18
Global Thematic Partners
New York
$16.7M +$693K +20,045 +4%
NAMA
19
Nikko Asset Management Americas
New York
$15.8M +$15.2M +440,120 +47,632%
Franklin Resources
20
Franklin Resources
California
$15.2M -$1.89M -54,750 -11%
VCM
21
Valiant Capital Management
California
$9.71M – – –
Morgan Stanley
22
Morgan Stanley
New York
$9.6M +$2.61M +75,437 +39%
Fidelity Investments
23
Fidelity Investments
Massachusetts
$8.66M -$2.54M -73,500 -23%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$8.55M -$8.08M -233,700 -49%
Susquehanna International Group
25
Susquehanna International Group
Pennsylvania
$6.85M -$462K -13,357 -7%
1
2 3 4 5

CRSP Hedge Fund Activity: Q1 2019 in Review

170 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2019, worth a combined $929M — up 47% from $631M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CRSP positions and 23 closed out — a net gain of 16 holders — while 44 added to existing stakes and 38 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $57.7M. The largest seller was Farallon Capital Management, cutting an estimated $18.2M.

  • 170 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $929M of CRISPR Therapeutics stock for Q1 2019, up 47% quarter-over-quarter.
  • 39 funds opened new CRISPR Therapeutics positions in Q1 2019 and 23 closed out, a net change of +16 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2019 was EcoR1 Capital, an estimated $57.7M added.
  • The largest CRISPR Therapeutics seller in Q1 2019 was Farallon Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.